Optiscan has been featured in Stockhead, The Australian and 11 News Corp mastheads in an article highlighting how Australian companies are boosting efficiency in healthcare and pharmaceutical manufacturing.

The article outlines how Optiscan is transforming pathology from a slow, multi-step manual process into a faster, smarter, real-time workflow with its live digital imaging at the cellular level. By providing instant, high-resolution images during medical procedures, the technology can accelerate diagnosis, reduce the need for repeat surgeries, and minimise reliance on lengthy lab analysis.

Recent developments include the unveiling of InForm, a first-in-class digital pathology device designed to speed diagnosis across the entire workflow from initial tissue contact, as well as a cloud-based telepathology platform (developed with Prolucid Technologies) enabling secure, real-time collaboration between surgeons and pathologists – a potential game changer for regional and remote healthcare.

"The faster and smarter we work, the sooner patients get the treatment they need. The real breakthrough isn’t just in the device itself – it’s in how efficiently we can get it from R&D to the patient’s bedside. If we can build smarter and deliver smarter, then we’re not just making devices – we’re making time, savings, and better outcomes for everyone in the healthcare chain,” said Optiscan CEO Dr. Camile Farah.

Stockhead – Read the full article here.
The Australian – Read the full article here.